(S)-3-[2-(2-Naphthalen-1-yl-ethoxy)-4-piperidin-1-yl-benzenesulfonylamino]-4-oxo-butyric Acid | 475213-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-3-[2-(2-Naphthalen-1-yl-ethoxy)-4-piperidin-1-yl-benzenesulfonylamino]-4-oxo-butyric Acid
• 英文别名: (3S)-3-[[2-(2-naphthalen-1-ylethoxy)-4-piperidin-1-ylphenyl]sulfonylamino]-4-oxobutanoic acid
• CAS: 475213-92-4
• 化学式: C₂₇H₃₀N₂O₆S
• 分子量: 510.611
• InChiKey: XEQSFFCPVWWKHC-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Arylsulfonamide ethers, and methods of use thereof
  申请人：——

  公开号：US20030096826A1

  公开（公告）日：2003-05-22

  Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1&bgr; converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.

  描述了新型芳基磺酰胺醚化合物及其药物组合物。还描述了将这些新型芳基磺酰胺醚化合物和药物组合物用作干扰素γ转化酶和其他ICE家族半胱氨酸蛋白酶的抑制剂的用途。此外，还描述了使用本发明的化合物或其药物组合物治疗中风、炎症性疾病、脓毒性休克、再灌注损伤、阿尔茨海默病和志贺氏菌病的方法。
• ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF
  申请人：Abbott GmbH & Co. KG

  公开号：EP1392280A2

  公开（公告）日：2004-03-03
• EP1392280A4
  申请人：——

  公开号：EP1392280A4

  公开（公告）日：2005-11-30
• US6875765B2
  申请人：——

  公开号：US6875765B2

  公开（公告）日：2005-04-05
• [EN] ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF<br/>[FR] ETHERS ARYLSULFONAMIDE ET TECHNIQUES D'UTILISATION DE CES COMPOSES
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2002089749A2

  公开（公告）日：2002-11-14

  Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family is also described. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.